Chemical strucutre of α-D-glucosamine
Find information on thousands of medical conditions and prescription drugs.

Glucosamine

Glucosamine (C6H14NO5) is a dietary supplement distributed as a salt — usually as glucosamine HCl, glucosamine sulfate potassium, or glucosamine sulfate sodium. A typical dosage is 1,500 mg per day. The salt complexes, glucosamine sulfate * KCl or glucosamine sulfate * NaCl, or the hydrochloride, glucosamine sulfate * HCl, are required for stabiliity. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
Gabapentin
Gabitril
Galantamine
Gamma-hydroxybutyrate
Ganciclovir
Garamycin
Gaviscon
Gemcitabine
Gemfibrozil
Gemhexal
Gemzar
Generlac
Gentamicin
Geodon
Gleevec
Gliadel
Gliadel Wafer
Glibenclamide
Glimepiride
Glipizide
Glucagon
Glucobay
Glucohexal
Glucophage
Glucosamine
Glucotrol
Glutethimide
Golytely
Gonadorelin
Goserelin
Gramicidin
Gramicidin S
Granisetron
Grifulvin V
Griseofulvin
Guaifenesin
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Glucosamine sulfate is a synthetic version of a compound the human body makes to stimulate the growth of cartilage. The idea is that such compounds help rebuild cartilage and reduce the symptoms of arthritis.

The supplement is an acceptable treatment in veterinary medicine, but the Arthritis Foundation and the American College of Rheumatology have not yet officially recommended it for humans, despite a large body of evidence supporting its use and the fact that it is considered a drug in several countries around the world. The United States Food and Drug Administration does not approve any dietary supplement, and, as such, at this time glucosamine is sold as a nutritional supplement and therefore does not need evidence of safety and efficacy. Glucosamine has been studied for over 20 years. As a natural substance that is already present inside the body, evidence bears out that glucosamine appears to be quite safe. One caveat - there is limited evidence that individuals with an allergy to shellfish should avoid glucosamine, as it is is usually derived from shellfish. There are vegetarian sources available.

Current research shows it may play a role in relieving pain associated with osteoarthritis. As used, it is often paired with MSM. The National Institutes of Health conducted a multi-arm, placebo-controlled study to see the effects of chondroitin and glucosamine on osteoporosis and osteoarthritis. Recent results of a 6-month clinical trial indicate that chondroitin sulfate (1.2 g) plus glucosamine (1.5 g) daily were as effective in relieving osteoarthritic knee pain as Celebrex, but more study would be helpful.

Read more at Wikipedia.org


[List your site here Free!]


Does glucosamine relieve arthritis joint pain? - Clinical inquiries: from the family practice inquiries network
From Journal of Family Practice, 8/1/03 by David C. Miller

* EVIDENCE-BASED ANSWER

Glucosamine may provide some pain relief. Studies have shown varied results, ranging from glucosamine being superior or equivalent to other agents, to no difference between glucosamine and placebo. However, most of these studies have small sample sizes, short duration, and often other significant flaws. Meta-analyses of available studies suggest a trend toward benefit from glucosamine (strength of recommendation: B).

Glucosamine may help osteoarthritis pain, but it is premature to recommend it universally until better studies are done. Even if glucosamine is effective, this sector of the market is currently unregulated, and products may not contain the amount or kind of glucosamine material advertised on their labels.

* EVIDENCE SUMMARY

Multiple methodological flaws have characterized studies trying to answer this question over the past 30 to 35 years. The companies manufacturing glucosamine have funded most studies. The overwhelming proportion of positive but marginal results raises the possibility of a publication bias (the tendency to publish only positive or supportive results), and the funding sources for the positive studies make that bias plausible.

Identified flaws in the studies include small sample size, inconsistent diagnostic criteria, variable disease sites, differing routes of administration, inconsistent doses, compositions and forms of glucosamine, the brief durations of studies, and poorly defined endpoints. (1) Those problems account for the relatively low quality scores of the studies used in meta-analyses, particularly in earlier ones. Quality scores range from 12% to 52% of optimal and make any definitive conclusions suspect. (2)

The magnitude of the treatment effect is variable. Meta-analyses demonstrate aggregate treatment effects ranging from 0.36 to 1.02--where a small effect is 0.2, a moderate effect is 0.5, and a large effect is 0.8. (2)

When more recent, higher-quality studies are analyzed, trends toward benefit and the effect sizes for glucosamine diminish but remain at aggregate values ranging from 0.26 to 0.44. (2-4) Statistically significant differences exist in some subgroup analyses and secondary endpoints. (5) Typical trends suggest that glucosamine is superior to placebo for pain relief, and less effective but safer than nonsteroidal anti-inflammatory agents. (5)

Statements about safety are speculative given the brief duration of available trials, most of which lasted <10 weeks. (6) Reported adverse effects are few. Mild gastrointestinal, skin, and constitutional symptoms predominate, but seldom at rates much higher than placebo. (3-4) Pain relief may require as much as 4 to 6 weeks of therapy, and short studies may not demonstrate these benefits. The possibility of site-specific benefits or a difference in effect from a different dose or form is impossible to determine based on the current literature.

* RECOMMENDATIONS FROM OTHERS

The American College of Rheumatology Subcommittee on Osteoarthritis believes that it is too early to issue recommendations for use of glucosamine sulfate or chondroitin sulfate for treatment of osteoarthritis. (7)

The National Institutes of Health Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) began recruiting in May 2002. The design of this study is specifically directed at addressing the flaws of previous studies. This study will enroll 1588 patients at 13 study sites, and will use standardized products and doses with a single route of administration in a double-blinded, placebo-controlled fashion.

The GAIT study will measure change in joint space width (baseline to 2 years) and consists of 4 arms: glucosamine vs placebo, chondroitin vs placebo, glucosamine and chondroitin vs placebo, and celecoxib vs placebo. It is likely that the National Institute of Arthritis, Musculoskeletal and Skin Diseases, in collaboration with the National Center for Complementary and Alternative Medicine, will issue recommendations regarding the efficacy of glucosamine when the study is complete in 2005 or 2006. Updates are available at http://nccam.nih.gov/clinicaltrials/ glucosamine.htm.

David C. Miller, MD, MBA, FAAFP, Cabarrus

Family Medicine Residency, Concord, NC;

Julie Richardson, MLS, Wake Forest University School

of Medicine, Northwest Area Health Education Center,

Winston-Salem, NC

* CLINICAL COMMENTARY

Patients frequently ask me if glucosamine, in combination with chondroitin or methylsulfonylmethane (MSM), reduces or prevents arthritis pain. It appears that glucosamine is safe and offers some promise.

I think a 6-week trial in patients with osteoarthritis is reasonable, preferably using glucosamine--a type that complies with the United States Pharmacopia/National Formulary standards--500 mg orally 3 times daily, once it becomes widely available. In my experience, very few patients who give glucosamine an enthusiastic and adequate trial of therapy continue the course for more than a few months. Those who use it longer often acknowledge only modest relief but continue with the hope of preventing further joint degeneration and increased pain, another currently unsubstantiated expectation.

Russell W. Roberts, MD, Louisiana State University Health Sciences Center, Shreveport, La

REFERENCES

(1.) Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25:379-395.

(2.) McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283:1469-1475.

(3.) Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998; 32:57-579.

(4.) Heyneman CA, Rhodes RS. Glucosamine for osteoarthritis: cure or conundrum? Ann Pharmacother 1998; 32:602-603.

(5.) Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26:2423-2430.

(6.) Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001; (1):CD002946.

(7.) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on 0steoarthritis Guidelines. Arthritis Rheum 2000; 43:1905-1915.

COPYRIGHT 2003 Dowden Health Media, Inc.
COPYRIGHT 2003 Gale Group

Return to Glucosamine
Home Contact Resources Exchange Links ebay